These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3802748)

  • 1. Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid.
    Barry AL; Gardiner RV; Packer RR
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):77-9. PubMed ID: 3802748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.
    Piddock LJ; Diver JM; Wise R
    Eur J Clin Microbiol; 1986 Aug; 5(4):411-5. PubMed ID: 3758052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activities of ten different fluoroquinolones against selected Enterobacteriaceae.
    Barry AL; Gardiner RV; Packer RR
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):81-3. PubMed ID: 3802749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro studies of S-25930 and S-25932, two new 4-quinolones.
    Piddock LJ; Andrews JM; Diver JM; Wise R
    Eur J Clin Microbiol; 1986 Jun; 5(3):303-10. PubMed ID: 2943589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
    Thabaut A; Durosoir JL
    Pathol Biol (Paris); 1982 Jun; 30(6):394-7. PubMed ID: 6810283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in nalidixic acid resistance in nontyphoidal Salmonella isolated from 1999 to 2002: decreased susceptibility to 6 fluoroquinolones.
    Rodriguez-Avial I; Rodriguez-Avial C; López O; Picazo JJ
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):261-4. PubMed ID: 15893900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal effect of combinations of nalidixic acid and various antibiotics on Enterobacteriaceae.
    Michel J; Luboshitzky R; Sacks T
    Antimicrob Agents Chemother; 1973 Sep; 4(3):201-4. PubMed ID: 4758830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Heessen FW; Muytjens HL
    Antimicrob Agents Chemother; 1984 Jan; 25(1):123-4. PubMed ID: 6230988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of changes in pH, medium and inoculum size on the in vitro activity of different quinolone and fluoroquinolone antibiotics against urinary pathogens.
    Gesu GP; Eftimiadi C; Debbia E; Schito GC
    Drugs Exp Clin Res; 1987; 13(2):79-84. PubMed ID: 3556122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activity of cinoxacin in vitro.
    Giamarellou H; Jackson GG
    Antimicrob Agents Chemother; 1975 May; 7(5):688-92. PubMed ID: 1096811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevalence of qnr genes in clinical Enterobacteriaceae non-susceptible to fluoroquinolone in Poland].
    Piekarska K; Rzeczkowska M; Zacharczuk K; Chróst A; Januszkiewicz A; Bareja E; Olak M; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(3):211-9. PubMed ID: 23285775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic activity of some chinolinic compounds combined with beta-lactam antibiotics against gram-positive and gram-negative clinical isolates.
    Ravagnan G; Piccolomini R; Speciale AM; Russo G; Renzini G
    Chemotherapy; 1985; 31(3):191-9. PubMed ID: 3996087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is nalidixic acid screening still valid for the detection of reduced susceptibility of fluoroquinolone with Salmonella Typhi?
    Irfan S; Jabeen K; Jilani UA; Ahmed B; Mehraj J; Ahsan T; Zafar A
    J Infect Dev Ctries; 2012 Oct; 6(10):700-3. PubMed ID: 23103891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.